Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
- Conditions
- Amyotrophic Lateral Sclerosis
- Registration Number
- NCT00021697
- Lead Sponsor
- Avanir Pharmaceuticals
- Brief Summary
The purpose of this study is to compare and evaluate the safety of AVP-923 (dextromethorphan/quinidine) for the treatment of emotional lability in ALS patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (17)
Loma Linda University Dept. of Neurology
🇺🇸Loma Linda, California, United States
UCLA School of Medicine Dept. of Neurology
🇺🇸Los Angeles, California, United States
University of California, San Francisco
🇺🇸San Francisco, California, United States
University of Colorado Health Sciences
🇺🇸Denver, Colorado, United States
University of Miami Dept. of Neurology
🇺🇸Miami, Florida, United States
Northwestern Medical School
🇺🇸Chicago, Illinois, United States
Johns Hopkins University
🇺🇸Baltimore, Maryland, United States
Massachusetts General Hospital
🇺🇸Boston, Massachusetts, United States
Columbia-Presbyterian Center Neurological Institute
🇺🇸New York, New York, United States
State University of New York
🇺🇸Syracuse, New York, United States
Scroll for more (7 remaining)Loma Linda University Dept. of Neurology🇺🇸Loma Linda, California, United States